Diagnostics and Biotech

Preimplantation Genetics Diagnosis (PGD) Market Research Report

Posted on Updated on

Allied Market Research added new research report on “Preimplantation Genetics Diagnosis (PGD) Market” includes Industry Size, Share, Trends, Growth, Demand, Supply, Market Development, Analysis and Forecast

Around 30 to 60% of the human embryos have chromosomal abnormalities. They usually occur in women aged 40 and above. Moreover, chromosomal abnormalities are also seen in working women due to the hectic lifestyle patterns which increase the demand of various diagnostic procedures including PGD.

Preimplantation Genetics Diagnosis Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $121 million by 2022, registering a CAGR of 6.14% during the period 2016-2022.

Get Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/1470

According to the World Health Organization (WHO), around 48.5 million couples worldwide were unable to conceive child in 2010. Furthermore, increasing risk of fatal genetic, hereditary, and chromosomal diseases such as duchenne muscular dystrophy, down syndrome, cystic fibrosis, triploidy, and thalassemia promote patients to opt for PGD thereby, boosting the market growth worldwide. Furthermore, increase in awareness about innovative and advanced application of PGD in the developing countries such as China and India offers enormous opportunities for the market growth. Rise in awareness about the various genetic disorders and chromosomal abnormalities have increased the demand of diagnostic procedures including PGD.

Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Geographically, Europe holds the highest potential to generate major revenue of the global market accounting for about 31.8% share in 2015. While Asia-Pacific is the fastest growing region registering a CAGR of 6.7%.

Browse Full Report @ https://www.alliedmarketresearch.com/preimplantation-genetic-diagnosis-market

Key Findings of Preimplantation Genetics Diagnosis Market Study:

  • Around 30% to 60% of the human embryos have chromosomal abnormalities. Chromosomal abnormalities in the embryo are usually occurs in the women aged 40 or over.
  • Almost 33% of the top strategies were merger and acquisition; whereas, business expansion, partnership and product launch accounted for 25%, 22.22% and 19.44% respectively of the overall key strategies.
  • Pricing of PGD tests is expected to witness a decline with increase in the volume of PGD testing
  • Chromosomal Abnormalities test generates the largest share in terms of revenue for PGD market
  • HLA Typing and Gender Selection based tests are the two fastest growing segments within Preimplantation Genetics Diagnosis market.

The key market players are F. Hoffmann-La Roche AG, Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Advertisements

Global Blood Market Expected to Reach $45,982 Million, by 2023

Posted on Updated on

According to a new report published by Allied Market Research, titled, “Blood Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global blood market was valued at $33,500 million in 2016, and is projected to reach $45,982 million by 2023, registering a CAGR of 4.6% from 2017 to 2023. The blood therapeutics segment contributed the highest share in 2016, owing to the increase in the demand for various plasma proteins for the recovery of patients.

Access Full Summary at: https://www.alliedmarketresearch.com/blood-market

The blood market products include whole blood collection, source plasma collection, blood therapeutics, blood typing products, blood screening, and blood processing equipment & associated products. Increase in geriatric population, rise in trauma cases, technological advancement in medical technology for donor screening, and advancement in blood transfusion instruments drive the market growth. However, rise in minimal invasive technology, which no longer require the blood transfusion hamper the market growth. Increase in peripheral nerve injuries and improvement in the healthcare facilities in Asia-Pacific provide growth opportunities for the market.

Blood & blood component banks contributed the highest share in 2016, owing to the increase in the demand for using equipment for the blood processing and for segregation of the blood components. North America accounted for significant share in the global market in 2016, owing to an established healthcare industry and rise in number of patient population requiring blood & blood components.

Do enquiry for sample report at: https://www.alliedmarketresearch.com/request-sample/2297

Key Findings of the Blood Market:

  • In 2016, the blood therapeutics segment accounted for the highest share of the global blood industry market.
  • The intravenous immunoglobulin segment contributed the highest revenue to the global market in 2016.
  • The blood & blood component banks segment is projected to grow at the highest CAGR of 4.9% during the forecast period.
  • North America is projected to grow at a CAGR of 4.4%.

The major companies profiled in the report include Abbott Laboratories, Baxter International Inc., Becton, Dickinson & Co., CSL Behring, Immucor, Novartis, Novo Nordisk, Ortho Clinical Diagnostics, Roche Diagnostics, and Grifols International SA.

Do enquiry before purchasing report at: https://www.alliedmarketresearch.com/purchase-enquiry/2297

Precision Medicine Market Is Expected to Reach $7,746 Million, Globally, by 2023

Posted on Updated on

According to a new report published by Allied Market Research, titled, Precision Medicine Market by Technology, Application and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global precision medicine market accounted for $3,516 million in 2016, and is estimated to reach at $7,746 million by 2023, registering a CAGR of 11.9% from 2017 to 2023. North America was the highest contributor in the precision medicine market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

Access Full Summary at: https://www.alliedmarketresearch.com/precision-medicine-market

Precision medicine is novel approach toward disease treatment in healthcare, medications are customized based on patients personalized healthcare needs such as, influence of genes & surrounding environment on patients health and result of various tests carried out on various levels. Follow-up on tests and treatment can be planned based on response of the patients toward treatment, which reduces side effects of drug and multiple administration of medications.

The precision medicine market is expected to grow at a productive rate the during forecast period. Surge in global incidence of cancer and increase in aging population susceptible to diseases are expected to boost the demand of precision medicines. Government initiatives & grants and private companies investing in R&D of precision medicines boost the market growth. However, strict regulation set by governments and risk associated with sharing genetic data of patients impedes the growth of precision medicine market.

Drug discovery generated the highest revenue in 2016, and is anticipated to continue this trend in the future. The requirement of quality drugs and versatile therapies for treatment is expected to boost the growth of this segment. Gene sequencing grows at a surprising rate and is expected to continue to grow during the forecast period.

Do enquiry for sample report at: https://www.alliedmarketresearch.com/request-sample/2311

North America holds the highest market share in 2016 owing to high prevalence rate of cancer and modern healthcare facilities. Moreover, adoption of experimental medicines and growth in awareness about precision medicines is expected to boost the North America market. However, Asia-pacific region is expected to grow at the highest CAGR during the forecast period considering, swift industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Key Findings of the Precision Medicine Market:

  • The sequencing by synthesis segment is projected to grow at the highest CAGR during the analysis period.
  • Consumables segment generated the highest revenue and is expected to continue its dominance in future.
  • North America dominated the market and is projected to grow at a CAGR of 11.0%.
  • China is expected to grow at the highest CAGR of 16.8% in Asia-Pacific.
  • The epigenomics segment is anticipated to grow at the highest CAGR of 14.1% during the forecast period.

The key companies profiled in the report include Roche Holding AG, Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly & Company.

Do enquiry before purchasing at: https://www.alliedmarketresearch.com/purchase-enquiry/2311

Global Epigenetics Market Is Expected to Reach $1,321 Million, by 2023

Posted on Updated on

According to a new report published by Allied Market Research, titled, “Epigenetics Market by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global epigenetics market was valued at $555 million in 2016, and is projected to reach $1,321 million by 2023, growing at a CAGR of 13.1% from 2017 to 2023. The DNA-modifying enzymes segment witnessed the highest rate, generating maximum revenue in the market in 2016.

Access Full Summary at: https://www.alliedmarketresearch.com/epigenetics-market

Epigenetics is an area of developmental biology that involves the study of cellular and physiological trait variations initiated by external or ecological aspects. This external stimulus swipe genes on and off and affect the ability of cells to read genes. Epigenetics changes the organisms phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. For instance, DNA methylation and histone modification are epigenetic processes wherein the alteration in gene expression is observed without the change in the DNA sequence. The increase in usage and application of epigenetics to formulate drugs to treat different oncology and non-oncology related diseases is expected to boost the market growth.

epigenetics-market-segmentation

The major factors that drive the global epigenetics market are rise in cancer prevalence; improved funding & aids for R&D activities, surge in partnership between academic, pharmaceutical, and biotechnology companies, and increased application of epigenetics in non-oncology diseases. However, high cost of instruments and lack of trained professionals are factors that impede the growth of this market. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.

The kits & assays product segment occupies the highest share in epigenetics product market, owing to their sheer usage and need throughout the protocol and other pre-requisite steps of DNA analysis. The next-generation sequencers segment witnessed the highest growth rate, and accounted for over half of the total share in 2016, and is anticipated to dominate the market. This is attributed to most of the epigenetic investigations that utilize this technology to achieve their desired objective.

Do enquiry for sample research at: https://www.alliedmarketresearch.com/request-sample/846

At present, oncology dominates the application segment and is expected to grow at a CAGR of 12.8% during the forecast period. Drugs based on epigenetics are reported to be incredibly effective and aid reverse abnormal gene expression. Abnormal gene expression causes an array of different diseases, especially cancer and respiratory diseases.

Key Findings of the Epigenetics Market:

  • The kit & assays product segment is anticipated to grow at the highest CAGR from 2017 to 2023.
  • The oncology application segment is expected to witness the highest growth rate during the forecast period.
  • The academic & government research institutes segment generated the highest revenue in 2016, and is expected to continue its dominance in the near future.
  • North America dominated the global epigenetics market, and is projected to grow at a CAGR of 12.3%.
  • Asia-Pacific is expected to witness the highest growth rate during the forecast period.

The major companies profiled in the report include Abcam plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation.

Do enquiry before purchasing at: https://www.alliedmarketresearch.com/purchase-enquiry/846

Global Liquid Biopsy Market Expected to Reach $3,805 Million, by 2023

Posted on Updated on

Liquid Biopsy Market Report, published by Allied Market Research, forecasts that the global market accounted for $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. North America was the highest contributor in the liquid biopsy market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

Access Full Summary at: https://www.alliedmarketresearch.com/liquid-biopsy-market

Liquid biopsy tests prove to be an easy and non-invasive method to access to molecular information about the tumor genome. Moreover, these tests facilitate early detection of cancer recurrence and characterization of tumor dynamics. Safety and efficiency of cancer treatment is improved by the use of these tests, owing to their ability to characterize new lesions, implement apt therapeutic targets, and predict the treatment outcome.

The advantages of implementing liquid biopsy over conventional methods of solid tissue biopsy are expected to boost the growth of the market. The advantages of liquid biopsies, such as minimally invasiveness and metastatic relapse evaluation, are expected to increase the demand for these tests. Furthermore, the increase in disposable income among cancer patients, surge in prevalence of cancer cases, and patient preference for minimally invasive therapies are anticipated to fuel the market growth. Rise in healthcare expenditure in the developing countries, such as India and China, and use of liquid biopsy tests to treat rare cancers are expected to present multiple opportunities for market growth. However, this growth is restricted, owing to alternatives to liquid biopsies and unclear reimbursement & regulation scenario.

Reagent was the highest revenue contributor in 2016, and is anticipated to continue this trend in the future. The requirement of reagents to execute liquid biopsy tests and their applicability are expected to boost the growth of this segment.

Do enquiry for sample research at: https://www.alliedmarketresearch.com/request-sample/1891

Lung cancer dominates the cancer by type segment of liquid biopsy market. The U.S. Food and Drug Administration (FDA) has also approved a liquid biopsy companion diagnostic test called cobas EGFR mutation test v2 to identify patients with metastatic non-small cell lung cancer (NSCLC) In addition, the growth in prevalence of lung cancer has contributed to provide lucrative opportunities in the market.

In 2016, North America accounted for highest contribution to the total revenue generated, owing to the high prevalence rate of cancer and high adoption rate of novel liquid biopsy tests. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure.

Key Findings of the Liquid Biopsy Market:

  • The government & academic research center segment is projected to grow at the highest rate during the analysis period.
  • Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its dominance in future.
  • North America dominated global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.
  • China is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.
  • The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.

The key companies profiled in the report include Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG , Bio-Rad Laboratories Inc., Myriad Genetics , Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.

Do enquiry before purchasing at: https://www.alliedmarketresearch.com/purchase-enquiry/1891

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

Rahul Thakur

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

Toll Free : +1-800-792-5285

UK : + 44-845-528-1300

Hong Kong : + 852-301-84916

India (Pune) : +91 20 66346060

Fax : +1⟨855⟩550-5975

help@alliedmarketresearch.com

Website: https://www.alliedmarketresearch.com

Blog: https://blog.alliedmarketresearch.com

Global miRNA Tools and Services Market to reach $620 Million, by 2022

Posted on Updated on

miRNA Tools and Services Market Report, published by Allied Market Research, forecasts that the global market was valued at $146 million in 2015 and is expected to garner $620 million by 2022, registering a CAGR of 23.4% during the forecast period 2016 – 2022. Research tools segment held nearly four-fifths share of the total market in 2015.

Access Full Summary at: https://www.alliedmarketresearch.com/mirna-tools-and-services-market

MicroRNAs(miRNAs) are a class of non-coding RNAs that play a major role in regulating gene expressions. These molecules work at the post-transcription level and modify the expression of around 30% of all mammalian protein-encoding genes. Use of bioinformatics and technologically advanced systems (such as NGS) and rise in incidence of chronic disorders drive the market growth. In addition, the ability of miRNAs to act as diagnostic biomarkers and predictors of drug response are anticipated to drive the demand for miRNA. However, the challenges related to the quantification and the development of in-house miRNA research tools such as microarrays restrict the market growth.

indonesia-mirna-tools-and-services-market

The qRT-PCR technology segment is expected to maintain its dominant position throughout the analysis period due to the increase in incidence of chronic diseases such as cancer and cardiovascular disorders. The rise in demand for the identification of miRNA in different organisms and their associated role as a diagnostic biomarker for the disease also boost the market growth.

Research and academic institutes segment dominated the market with more than two-fifths of the total market in 2015. This is primarily attributed to the increase in research projects undertaken to test the ability of miRNA as candidates of disease biomarkers.

Do Enquire for sample report at: https://www.alliedmarketresearch.com/request-free-sample/2103

Key Findings of the Study:

  • Research tools led the global miRNA tools and services market, and accounted for nearly four-fifths of the total market in 2015.
  • Functional studies services segment is projected to grow at highest CAGR of 31.2% during the forecast period.
  • CROs is the fastest growing segment and is expected to grow at a CAGR of 27.4% during the forecast period.
  • qRT-PCR technology segment occupied nearly one-third of the market in 2015.
  • In 2015 Japan was the major shareholder and accounted for almost one-third of the Asia-Pacific market.

North America led the overall market in 2015 and is expected to maintain its dominance throughout the forecast period. This is attributed to the increased funding for miRNA research and increase in incidence of chronic disorders such as cancer. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period owing to increase in investment by pharma and biotech companies in the emerging markets (such as India and China).

The major companies profiled in the report include QIAGEN (Exiqon), Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, GE Healthcare Dharmacon Inc., GeneCopoeia, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Merck & Co., Inc., and New England Biolabs.

Do Enquire before purchasing at: https://www.alliedmarketresearch.com/purchase-enquiry/2103

Global Optical Imaging Market – Opportunities and Forecasts, 2014 – 2022

Posted on Updated on

Optical ImagingAllied Market Research adds “World Optical Imaging Market” new report to its research database. The report provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market globally.

Optical imaging is the technique for taking images of the internal body parts non-invasively. Visible light and photons are used to take the detailed image of internal organs and tissues. It also takes images of smaller structures includes cells and molecules. These images are used by doctors for diagnosis and treatment of diseases and also by scientists for different research work.

Request sample report @ https://www.alliedmarketresearch.com/request-toc-and-sample/73

Optical imaging market is in emerging state mainly due to the use of non-ionizing radiations which reduces the radiation expose of patients. Also optical imaging has potential to differentiate between soft tissues using various properties of photons like absorption or scattering at different wavelengths. Furthermore, optical imaging is combined with different imaging techniques such as MRI or X-rays which provides enhanced images that is very useful for the study of complex diseases. Also, optical imaging can measure different properties of tissues and organs by using various colors of light with different wavelengths. However, factors such as high cost associated with the imaging process, stringent government policies and lack of skilled technicians are impeding the market growth.

Send Enquiry About Optical Imaging Market: https://www.alliedmarketresearch.com/purchase-enquiry/73

The world optical imaging market has been segmented based on technique, product, therapeutic area, application, end-user and geography. Based on technique, the market is segmented into optical coherence tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging and super resolution microscopy. Based on product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. By therapeutic area, market is segmented into neurology, oncology, ophthalmology, cardiology, dentistry, dermatology and others. Based on application, the market is segmented into pre-clinical and clinical research, pathological imaging and intra-operative imaging. Based on end-user, the market is segmented into diagnostic imaging centers, hospitals and research laboratories. The market is analyzed on the basis of four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

For any Queries Connect to Analyst: https://www.alliedmarketresearch.com/connect-to-analyst/73

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.